307 related articles for article (PubMed ID: 14614022)
1. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Tentori L; Leonetti C; Scarsella M; D'Amati G; Vergati M; Portarena I; Xu W; Kalish V; Zupi G; Zhang J; Graziani G
Clin Cancer Res; 2003 Nov; 9(14):5370-9. PubMed ID: 14614022
[TBL] [Abstract][Full Text] [Related]
2. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
Tentori L; Leonetti C; Scarsella M; Vergati M; Xu W; Calvin D; Morgan L; Tang Z; Woznizk K; Alemu C; Hoover R; Lapidus R; Zhang J; Graziani G
Int J Oncol; 2005 Feb; 26(2):415-22. PubMed ID: 15645126
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Tentori L; Portarena I; Barbarino M; Balduzzi A; Levati L; Vergati M; Biroccio A; Gold B; Lombardi ML; Graziani G
Mol Pharmacol; 2003 Jan; 63(1):192-202. PubMed ID: 12488552
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Tentori L; Leonetti C; Scarsella M; Muzi A; Vergati M; Forini O; Lacal PM; Ruffini F; Gold B; Li W; Zhang J; Graziani G
Eur J Cancer; 2005 Dec; 41(18):2948-57. PubMed ID: 16288862
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
Tentori L; Muzi A; Dorio AS; Scarsella M; Leonetti C; Shah GM; Xu W; Camaioni E; Gold B; Pellicciari R; Dantzer F; Zhang J; Graziani G
Curr Cancer Drug Targets; 2010 Jun; 10(4):368-83. PubMed ID: 20464779
[TBL] [Abstract][Full Text] [Related]
6. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Tentori L; Leonetti C; Scarsella M; Muzi A; Mazzon E; Vergati M; Forini O; Lapidus R; Xu W; Dorio AS; Zhang J; Cuzzocrea S; Graziani G
FASEB J; 2006 Aug; 20(10):1709-11. PubMed ID: 16809434
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
9. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.
Golden EB; Cho HY; Jahanian A; Hofman FM; Louie SG; Schönthal AH; Chen TC
Neurosurg Focus; 2014 Dec; 37(6):E12. PubMed ID: 25434381
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
Su JM; Thompson P; Adesina A; Li XN; Kilburn L; Onar-Thomas A; Kocak M; Chyla B; McKeegan E; Warren KE; Goldman S; Pollack IF; Fouladi M; Chen A; Giranda V; Boyett J; Kun L; Blaney SM
Neuro Oncol; 2014 Dec; 16(12):1661-8. PubMed ID: 24908656
[TBL] [Abstract][Full Text] [Related]
11. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
Palma JP; Wang YC; Rodriguez LE; Montgomery D; Ellis PA; Bukofzer G; Niquette A; Liu X; Shi Y; Lasko L; Zhu GD; Penning TD; Giranda VL; Rosenberg SH; Frost DJ; Donawho CK
Clin Cancer Res; 2009 Dec; 15(23):7277-90. PubMed ID: 19934293
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide: mechanisms of action, repair and resistance.
Zhang J; Stevens MF; Bradshaw TD
Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
[TBL] [Abstract][Full Text] [Related]
14. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
Dinca EB; Lu KV; Sarkaria JN; Pieper RO; Prados MD; Haas-Kogan DA; Vandenberg SR; Berger MS; James CD
Cancer Res; 2008 Dec; 68(24):10034-9. PubMed ID: 19074867
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Middleton MR; Friedlander P; Hamid O; Daud A; Plummer R; Falotico N; Chyla B; Jiang F; McKeegan E; Mostafa NM; Zhu M; Qian J; McKee M; Luo Y; Giranda VL; McArthur GA
Ann Oncol; 2015 Oct; 26(10):2173-9. PubMed ID: 26202595
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.
Tentori L; Leonetti C; Scarsella M; d'Amati G; Portarena I; Zupi G; Bonmassar E; Graziani G
Blood; 2002 Mar; 99(6):2241-4. PubMed ID: 11877304
[TBL] [Abstract][Full Text] [Related]
17. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
Robins HI; Zhang P; Gilbert MR; Chakravarti A; de Groot JF; Grimm SA; Wang F; Lieberman FS; Krauze A; Trotti AM; Mohile N; Kee AY; Colman H; Cavaliere R; Kesari S; Chmura SJ; Mehta M
J Neurooncol; 2016 Jan; 126(2):309-16. PubMed ID: 26508094
[TBL] [Abstract][Full Text] [Related]
19. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
Palma JP; Rodriguez LE; Bontcheva-Diaz VD; Bouska JJ; Bukofzer G; Colon-Lopez M; Guan R; Jarvis K; Johnson EF; Klinghofer V; Liu X; Olson A; Saltarelli MJ; Shi Y; Stavropoulos JA; Zhu GD; Penning TD; Luo Y; Giranda VL; Rosenberg SH; Frost DJ; Donawho CK
Anticancer Res; 2008; 28(5A):2625-35. PubMed ID: 19035287
[TBL] [Abstract][Full Text] [Related]
20. Recent approaches to improve the antitumor efficacy of temozolomide.
Tentori L; Graziani G
Curr Med Chem; 2009; 16(2):245-57. PubMed ID: 19149575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
